RCKT
Rocket Pharmaceuticals, Inc.
26.28
USD
This page is just a preview of the data found in TrendSpider’s full version
Rocket Pharmaceuticals, Inc. stock is up 34.29% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November. In the last 8 Unusual Options Trades, there were 3 PUTs, 5 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 12 Oct 18:38 | 20 Oct, 2023 | 22.50 | 580 | ||
| 13 Oct 15:11 | 20 Oct, 2023 | 17.50 | 3812 | ||
| 18 Oct 14:45 | 19 Apr, 2024 | 12.50 | 1 | ||
| 26 Oct 15:48 | 17 Nov, 2023 | 17.50 | 89 | ||
| 26 Oct 19:18 | 19 Apr, 2024 | 30.00 | 25 | ||
| 15 Nov 16:35 | 19 Jan, 2024 | 12.50 | 32 | ||
| 15 Nov 18:28 | 19 Jan, 2024 | 25.00 | 5351 | ||
| 30 Nov 15:10 | 19 Jan, 2024 | 30.00 | 0 |
Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells. The company also has a clinical stage in vitro virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure.
